Insulet Corp.'s (PODD) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product's market potential. The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% ...